Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis

References

• Griffiths CEM, van der Walt JM, Ashcroft DM, Flohr C, Naldi L, Nijsten T, Augustin M. The global state of psoriasis disease epidemiology: a workshop report. Br J Dermatol. 2017;177:e4–13. doi:10.1111/bjd.15610.
   PubMed Web of Science ®Google Scholar
• Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, Shin DB, Attor R, Troxel AB, Gelfand JM. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149:1173. doi:10.1001/jamadermatol.2013.5015.
   PubMed Web of Science ®Google Scholar
• ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S, ten Bergen LL. The TNF/IL‐23/IL‐17 axis—Head‐to‐head trials comparing different biologics in psoriasis treatment. Scand J Immunol [Internet]. 2020 2022 Oct 16;92. 10.1111/sji.12946
   Web of Science ®Google Scholar
• Li X, Bechara R, Zhao J, McGeachy MJ, Gaffen SL. IL-17 receptor–based signaling and implications for disease. Nat Immunol. 2019;20:1594–602. doi:10.1038/s41590-019-0514-y.
   PubMed Web of Science ®Google Scholar
• Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 Axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339–50. doi:10.1038/jid.2009.59.
   PubMed Web of Science ®Google Scholar
• Zou W, Wu Z, Xiang X, Sun S, Zhang J. The expression and significance of T helper cell subsets and regulatory T cells CD4 +CD25 + in peripheral blood of patients with human leukocyte antigen B27-positive acute anterior uveitis. Graefes Arch Clin Exp Ophthalmol. 2014;252:665–72. doi:10.1007/s00417-014-2567-9.
   PubMed Web of Science ®Google Scholar
• Jawad S, Liu B, Agron E, Nussenblatt RB, Sen HN. Elevated serum levels of interleukin-17A in uveitis patients. Ocul Immunol Inflamm. 2013;21:434–39. doi:10.3109/09273948.2013.815786.
   PubMed Web of Science ®Google Scholar
• Matusiak Ł, Szczęch J, Bieniek A, Nowicka-Suszko D, Szepietowski JC. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017;76:670–75. doi:10.1016/j.jaad.2016.10.042.
   PubMed Web of Science ®Google Scholar
• Kelly G, Hughes R, McGarry T, Born M, Adamzik K, Fitzgerald R, Lawlor C, Tobin AM, Sweeney CM, Kirby B. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol. 2015;173(6):1431–39. doi:10.1111/bjd.14075.
   PubMedGoogle Scholar
• Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122:939–48. doi:10.1016/j.ophtha.2014.12.033.
   PubMed Web of Science ®Google Scholar
• Casseres RG, Prussick L, Zancanaro P, Rothstein B, Joshipura D, Saraiya A, Turkowski Y, Au SC, Alomran A, Abdat R, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol. 2020;82:1524–26. doi:10.1016/j.jaad.2020.02.005.
   PubMed Web of Science ®Google Scholar
• Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J, Rolleri R, Seegobin S, Baeten D, Ionescu L, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a Phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol. 2021;157:1279. doi:10.1001/jamadermatol.2021.2905.
   PubMed Web of Science ®Google Scholar
• Farahnik B, Beroukhim K, Nakamura M, Abrouk M, Zhu TH, Singh R, Lee K, Bhutani T, Koo J. Anti-IL-17 agents for psoriasis: a review of Phase III data. J Drugs Dermatol JDD. 2016;15:311–16.
   PubMedGoogle Scholar
• Amin M, Darji K, No DJ, Bhutani T, Wu JJ. Review of IL-17 inhibitors for psoriasis. J Dermatol Treat. 2018;29:347–52. doi:10.1080/09546634.2017.1395796.
   PubMed Web of Science ®Google Scholar
• Brembilla NC, Senra L, Boehncke W-H. The IL-17 family of cytokines in psoriasis: iL-17A and beyond. Front Immunol. 2018;9:1682. doi:10.3389/fimmu.2018.01682.
   PubMed Web of Science ®Google Scholar
• Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160:319–24. doi:10.1111/j.1365-2133.2008.08902.x.
   PubMed Web of Science ®Google Scholar
• Liu S, Song X, Chrunyk BA, Shanker S, Hoth LR, Marr ES, Griffor MC. Crystal structures of interleukin 17A and its complex with IL-17 receptor a. Nat Commun. 2013;4:1888. doi:10.1038/ncomms2880.
   PubMed Web of Science ®Google Scholar
• Adams R, Maroof A, Baker T, Lawson ADG, Oliver R, Paveley R, Rapecki S, Shaw S, Vajjah P, West S, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894. doi:10.3389/fimmu.2020.01894.
   PubMed Web of Science ®Google Scholar
• Papp KA, Weinberg MA, Morris A, Reich K. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021;397:1564–75. doi:10.1016/S0140-6736(21)00440-2.
   PubMed Web of Science ®Google Scholar
• Iznardo H, Puig L. Dual inhibition of IL-17A and IL-17F in psoriatic disease. Ther Adv Chronic Dis. 2021;12:204062232110378. doi:10.1177/20406223211037846.
   Web of Science ®Google Scholar
• Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohrt A, Borg E, Warren RB, Cheungpasitporn W. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS One. 2019;14:e0220868. doi:10.1371/journal.pone.0220868.
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, De Cuyper D, Vanvoorden V, Madden C, et al. Bimekizumab versus Secukinumab in Plaque Psoriasis. N Engl J Med. 2021;385:142–52. doi:10.1056/NEJMoa2102383.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, et al. Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from Phase 2 and phase 3 randomized clinical trials. JAMA Dermatol. 2022;158:735. doi:10.1001/jamadermatol.2022.1185.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397:475–86. doi:10.1016/S0140-6736(21)00126-4.
   PubMed Web of Science ®Google Scholar
• Kaul M, Jarvis P, Rozenberg I, Kolbinger F, Di Padova F, Calonder C, Espie P, Rondeau JM, Cebe R, Huber T, et al. First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2021;35:1143–51. doi:10.1111/jdv.17071.
   PubMed Web of Science ®Google Scholar
• Reich K, Jackson K, Ball S, Garces S, Kerr L, Chua L, Muram TM, Blauvelt A. Ixekizumab pharmacokinetics, anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis. J Invest Dermatol. 2018;138:2168–73. doi:10.1016/j.jid.2018.04.019.
   PubMed Web of Science ®Google Scholar
• Pavelka K, Kivitz AJ, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Wang Y, Porter BO, Stefanska A, Richards HB, et al. Secukinumab 150/300 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3‐year results from the Phase 3 MEASURE 3 study. ACR Open Rheumatol. 2020;2:119–27. doi:10.1002/acr2.11102.
   PubMedGoogle Scholar
• Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, Shi Y. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2018;62:46–58. doi:10.1016/j.intimp.2018.06.020.
   PubMed Web of Science ®Google Scholar
• Sörensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, Orlova A, Sandström M, Lubberink M, Olofsson H, et al. Measuring HER2-receptor expression in metastatic breast cancer using [68 Ga]ABY-025 affibody PET/CT. Theranostics. 2016;6:262–71. doi:10.7150/thno.13502.
   PubMed Web of Science ®Google Scholar
• Zurdo J, Arnell A, Obrezanova O, Smith N, Gómez de la Cuesta R, Gallagher TRA, Michael R, Stallwood Y, Ekblad C, Abrahmsén L, et al. Early implementation of QbD in biopharmaceutical development: a practical example. Biomed Res Int. 2015;2015:1–19. doi:10.1155/2015/605427.
   Web of Science ®Google Scholar
• Peters T. All about albumin: biochemistry, genetics, and medical applications. San Diego: Academic Press; 1996.
   Google Scholar
• Coppieters K, Dreier T, Silence K, Haard HD, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Wiele CVD, Staelens L, et al. Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 2006;54:1856–66. doi:10.1002/art.21827.
   PubMed Web of Science ®Google Scholar
• Wunder A, Müller-Ladner U, Stelzer EHK, Funk J, Neumann E, Stehle G, Pap T, Sinn H, Gay S, Fiehn C. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol. 2003;170:4793–801. doi:10.4049/jimmunol.170.9.4793.
   PubMed Web of Science ®Google Scholar
• Grönwall C, Jonsson A, Lindström S, Gunneriusson E, Ståhl S, Herne N. Selection and characterization of affibody ligands binding to Alzheimer amyloid β peptides. J Biotechnol. 2007;128:162–83. doi:10.1016/j.jbiotec.2006.09.013.
   PubMed Web of Science ®Google Scholar
• Frejd FY, Klint S, Gudmundsdotter L, Höidén-Guthenberg I, Feldwisch J, Klaar M, Jensen M, Bejker D, Reich K. Safety and efficacy of subcutaneous ABY-035, a high-affinity IL-17A inhibiting affibody ligand trap, dosed biweekly during 12 weeks in psoriasis patients. Abstract 3630, e-poster number P2053, 27th EADV Congress Paris France. 2018.
   Google Scholar
• Ståhl S, Gräslund T, Eriksson Karlström A, Frejd FY, Nygren P-Å, Löfblom J. Affibody molecules in biotechnological and medical applications. Trends Biotechnol. 2017;35:691–712. doi:10.1016/j.tibtech.2017.04.007.
   PubMed Web of Science ®Google Scholar
• Nord K, Gunneriusson E, Ringdahl J, Ståhl S, Uhlén M, Nygren P-Å. Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain. Nat Biotechnol. 1997;15:772–77. doi:10.1038/nbt0897-772.
   PubMed Web of Science ®Google Scholar
• Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670–80. doi:10.1016/j.febslet.2010.04.014.
   PubMed Web of Science ®Google Scholar
• Frejd FY, Kim K-T. Affibody molecules as engineered protein drugs. Experimental & Molecular Medi. 2017;49:e306. doi:10.1038/emm.2017.35.
   PubMed Web of Science ®Google Scholar
• Kolbinger F, Di Padova F, Deodhar A, Hawkes JE, Huppertz C, Kuiper T, McInnes IB, Ritchlin CT, Rosmarin D, Schett G, et al. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacol Ther. 2022;229:107925. doi:10.1016/j.pharmthera.2021.107925.
   PubMed Web of Science ®Google Scholar
• Liu L, Kikly K, Lu J, Allan B, Tang Y, Tetreault J, Chow C-K, Barmettler B, Nelson J, Bina H, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016:39. doi:10.2147/JIR.S100940
   PubMedGoogle Scholar
• Neri D, Momo M, Prospero T, Winter G. High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J Mol Biol. 1995;246:367–73. doi:10.1006/jmbi.1994.0091.
   PubMed Web of Science ®Google Scholar
• Silacci M, Lembke W, Woods R, Attinger-Toller I, Baenziger-Tobler N, Batey S, Santimaria R, von der Bey U, Koenig-Friedrich S, Zha W, et al. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs. 2016;8:141–49. doi:10.1080/19420862.2015.1093266.
   PubMed Web of Science ®Google Scholar
• Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, Williams S, Cole MJ, Ross S, Schwall R. Imaging tumors with an albumin-binding fab, a novel tumor-targeting agent. Cancer Res. 2007;67:254–61. doi:10.1158/0008-5472.CAN-06-2531.
   PubMed Web of Science ®Google Scholar
• Eshwar V, Kamath A, Shastry R, Shenoy AK, Kamath P. A Review of the Safety of Interleukin-17A Inhibitor Secukinumab. Pharmaceuticals. 2022;15:1365. doi:10.3390/ph15111365.
   Web of Science ®Google Scholar
• Liu T, Li S, Ying S, Tang S, Ding Y, Li Y, Qiao J, Fang H. The IL-23/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol. 2020;11:594735. doi:10.3389/fimmu.2020.594735.
   PubMed Web of Science ®Google Scholar
• Barbieri MA, Cicala G, Cutroneo PM, Gerratana E, Palleria C, De Sarro C, Vero A, Iannone L, Manti A, Russo E, et al. Safety profile of biologics used in rheumatology: an Italian prospective pharmacovigilance study. J Clin Med. 2020;9:1227. doi:10.3390/jcm9041227.
   PubMed Web of Science ®Google Scholar
• Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res. 2019;2019:1–25.
   Web of Science ®Google Scholar
• Gerdes S, Staubach P, Dirschka T, Wetzel D, Weirich O, Niesmann J, da Mota R, Rothhaar A, Ardabili M, Vlasitz G, et al. Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II randomized, placebo-controlled, double-blinded, dose-finding multicentre study including long-term treatment. Under Review. 2023.
   Google Scholar
• Zhu B, Edson‐heredia E, Guo J, Maeda‐chubachi T, Shen W, Kimball AB. Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial. Br J Dermatol. 2014;171:1215–19. doi:10.1111/bjd.13065.
   PubMed Web of Science ®Google Scholar
• Kolbinger F, Loesche C, Valentin M-A, Jiang X, Cheng Y, Jarvis P, Peters T, Calonder C, Bruin G, Polus F, et al. β-Defensin 2 is a responsive biomarker of IL-17A–driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2017;139:923–32.e8. doi:10.1016/j.jaci.2016.06.038.
   PubMed Web of Science ®Google Scholar
• Fahrbach K, Sarri G, Phillippo DM, Neupane B, Martel SE, Kiri S, Reich K. Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis. Dermatol Ther. 2021;11:1965–98. doi:10.1007/s13555-021-00602-z.
   Web of Science ®Google Scholar
• Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79:277–86.e10. doi:10.1016/j.jaad.2018.03.037.
   PubMed Web of Science ®Google Scholar
• Lu T DC-806, an oral IL-17A inhibitor: proof-of-concept in adults with mild-to-moderate psoriasis. In: S042 - Late-breaking Research: Procedural Session 2. American Academy of Dermatology Annual Meeting, March 17-21, New Orleans, LA, USA. 2023.
   Google Scholar
• Johansson S, Skoog B. Rapid silver staining of polyacrylamide gels. J Biochem Biophys Meth. 1987;33:33. doi:10.1016/0165-022X(87)90087-X.
   Google Scholar